Jan 25, 2021
Deepak Khatry, Ph.D., a Westat Associate Director and a clinical trials biostatistician, has written Evidence Derived from Real-World Data (RWD): Utility, Constraints, and Cautions, the second chapter in a new book: Real-World Evidence in Drug Development and Evaluation, published in 2021 under the Biostatistics Series of Chapman & Hall/CRC Press.
Dr. Khatry addresses
- What RWD is in the context of drug development and clinical practice
- Why RWD is important
- How RWD can be useful
- Study designs and statistical methods necessary to ensure high-quality real-world evidence (RWE)
He concludes with actual biopharmaceutical examples and a summary of findings. He also provides cautions and recommendations to researchers and practitioners on the generation and use of real-world evidence.
Written for pharmaceutical industry and clinical practitioners by experienced researchers in the pharmaceutical industry, the book is a single and comprehensive resource to learn about RWE, an emerging and important area of research and application at the forefront of pharmaceutical innovations. The book contains a wide range of real-world evidence examples with applications throughout the lifecycle of drug product development and evidence evaluation.
Westat CLS—Showcasing CRO Services to Commercial Clients
What Pneumonia Vaccine Prompts the Best Immunity Response in Infants Whose Mothers Have HIV?
First Next-Generation Freeze-Dried Plasma (FDP) Product Found to Be as Safe and Potent as Fresh Frozen Plasma (FFP)